US5977144A
(en)
*
|
1992-08-31 |
1999-11-02 |
University Of Florida |
Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
|
US5852041A
(en)
*
|
1993-04-07 |
1998-12-22 |
Sibia Neurosciences, Inc. |
Substituted pyridines useful as modulators of acethylcholine receptors
|
JP3899126B2
(ja)
*
|
1995-01-06 |
2007-03-28 |
ターガセプト,インコーポレイテッド |
中枢神経系疾患の予防及び治療のための医薬組成物
|
US5597919A
(en)
*
|
1995-01-06 |
1997-01-28 |
Dull; Gary M. |
Pyrimidinyl or Pyridinyl alkenyl amine compounds
|
US5616707A
(en)
*
|
1995-01-06 |
1997-04-01 |
Crooks; Peter A. |
Compounds which are useful for prevention and treatment of central nervous system disorders
|
US5824692A
(en)
*
|
1995-01-06 |
1998-10-20 |
Lippiello; Patrick Michael |
Pharmaceutical compositions for prevention and treatment of central nervous system disorders
|
US5731314A
(en)
*
|
1995-01-06 |
1998-03-24 |
Bencherif; Merouane |
Pharamceutical compositions for prevention and treatment of tourette's syndrome
|
US5585388A
(en)
*
|
1995-04-07 |
1996-12-17 |
Sibia Neurosciences, Inc. |
Substituted pyridines useful as modulators of acetylcholine receptors
|
US6194581B1
(en)
|
1995-04-07 |
2001-02-27 |
Merck & Co., Inc. |
Substituted pyridines useful as modulators of acetylcholine receptors
|
US5583140A
(en)
*
|
1995-05-17 |
1996-12-10 |
Bencherif; Merouane |
Pharmaceutical compositions for the treatment of central nervous system disorders
|
US5794887A
(en)
|
1995-11-17 |
1998-08-18 |
Komerath; Narayanan M. |
Stagnation point vortex controller
|
US5616716A
(en)
*
|
1996-01-06 |
1997-04-01 |
Dull; Gary M. |
(3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
|
DK0900200T5
(da)
|
1996-04-23 |
2010-01-11 |
Targacept Inc |
Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet
|
US5663356A
(en)
*
|
1996-04-23 |
1997-09-02 |
Ruecroft; Graham |
Method for preparation of aryl substituted alefinic secondary amino compounds
|
US20020052497A1
(en)
*
|
2000-03-09 |
2002-05-02 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
US6166048A
(en)
*
|
1999-04-20 |
2000-12-26 |
Targacept, Inc. |
Pharmaceutical compositions for inhibition of cytokine production and secretion
|
US6979695B2
(en)
|
1996-04-23 |
2005-12-27 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
US5861423A
(en)
*
|
1997-02-21 |
1999-01-19 |
Caldwell; William Scott |
Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
|
US6531606B1
(en)
*
|
1997-02-21 |
2003-03-11 |
Targacept, Inc. |
Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
|
US5811442A
(en)
*
|
1997-02-21 |
1998-09-22 |
Bencherif; Merouane |
Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
|
US7214686B2
(en)
*
|
1997-06-30 |
2007-05-08 |
Targacept, Inc. |
Pharmaceutical compositions and methods for effecting dopamine release
|
PT1056458E
(pt)
*
|
1998-02-24 |
2005-08-31 |
Univ Wake Forest |
Tratamento de dor cronica
|
JP2002510619A
(ja)
|
1998-04-02 |
2002-04-09 |
アール・ジェイ・レイノルズ・タバコ・カンパニー |
薬剤組成物及びその使用法
|
US6232316B1
(en)
|
1998-06-16 |
2001-05-15 |
Targacept, Inc. |
Methods for treatment of CNS disorders
|
US7790757B2
(en)
*
|
1998-06-16 |
2010-09-07 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
US20050131034A1
(en)
*
|
1998-06-16 |
2005-06-16 |
Caldwell William S. |
Compounds capable of activating cholinergic receptors
|
US6218383B1
(en)
|
1998-08-07 |
2001-04-17 |
Targacept, Inc. |
Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
|
US6262124B1
(en)
*
|
1998-10-22 |
2001-07-17 |
Gary Maurice Dull |
Pharmaceutical compositions and methods for use
|
US6432975B1
(en)
|
1998-12-11 |
2002-08-13 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
US6953855B2
(en)
*
|
1998-12-11 |
2005-10-11 |
Targacept, Inc. |
3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
|
US20010031771A1
(en)
|
1999-05-24 |
2001-10-18 |
Gary Maurice Dull |
Pharmaceutical compositions and methods for use
|
US6455554B1
(en)
|
1999-06-07 |
2002-09-24 |
Targacept, Inc. |
Oxopyridinyl pharmaceutical compositions and methods for use
|
AU5326100A
(en)
*
|
1999-06-07 |
2000-12-28 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
US6890935B2
(en)
*
|
1999-11-01 |
2005-05-10 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
FR2810886B1
(fr)
*
|
2000-06-05 |
2002-12-27 |
Sanjuan Benito Arranz |
Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux)
|
US6852741B2
(en)
*
|
2001-12-31 |
2005-02-08 |
University Of Florida |
Compositions and methods for treatment of neurological disorders
|
WO2004012674A2
(en)
*
|
2002-08-02 |
2004-02-12 |
Nutraceutical Development Corporation |
Development of muscle mass in a mammal
|
PT1678172E
(pt)
*
|
2003-10-15 |
2010-03-03 |
Targacept Inc |
Composições farmacêuticas e métodos para alívio da dor e tratamento de perturbações do sistema nervoso central
|
JP4665109B2
(ja)
*
|
2004-04-02 |
2011-04-06 |
アルテリアル リモデリング テクノロジーズ, インコーポレイテッド |
ポリマーベースのステントアセンブリ
|
US7780981B2
(en)
|
2004-09-13 |
2010-08-24 |
Chrono Therapeutics, Inc. |
Biosynchronous transdermal drug delivery
|
US8252321B2
(en)
|
2004-09-13 |
2012-08-28 |
Chrono Therapeutics, Inc. |
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
|
UA88792C2
(ru)
*
|
2004-11-10 |
2009-11-25 |
Таргасепт, Інк. |
Гидроксибензоатные соли метаникотиновых соединений
|
US7459469B2
(en)
|
2004-11-10 |
2008-12-02 |
Targacept, Inc. |
Hydroxybenzoate salts of metanicotine compounds
|
CN101528698A
(zh)
*
|
2006-05-09 |
2009-09-09 |
阿斯利康公司 |
(2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式
|
TWI389889B
(zh)
*
|
2006-05-09 |
2013-03-21 |
Targacept Inc |
(2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型
|
AR062860A1
(es)
*
|
2006-09-15 |
2008-12-10 |
Astrazeneca Ab |
Combinaciones terapeuticas 482
|
JP5502494B2
(ja)
*
|
2007-01-22 |
2014-05-28 |
ターガセプト・インコーポレイテッド |
メタニコチンアナログの鼻腔内、バッカル、または舌下投与
|
ES2521494T3
(es)
*
|
2007-04-02 |
2014-11-12 |
Parkinson's Institute |
Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
|
AU2008282205A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Astrazeneca Ab |
Transdermal administration of (2S)-(4E)-N-methyl-5-(3-( 5-isopropoxypyridin)yl)-4-penten-2-amine
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
US8703802B2
(en)
|
2010-05-20 |
2014-04-22 |
Targacept, Inc. |
Process for the preparation of aryl substituted olefinic amines
|
WO2013006643A1
(en)
|
2011-07-06 |
2013-01-10 |
The Parkinson's Institute |
Compositions and methods for treatment of symptoms in parkinson's disease patients
|
EP3142669A2
(de)
*
|
2014-05-16 |
2017-03-22 |
Synaptec Development LLC |
Beseitigung von amyloid ss
|
CA2974324A1
(en)
|
2015-01-28 |
2016-08-04 |
Zita S. Netzel |
Drug delivery methods and systems
|
US10679516B2
(en)
|
2015-03-12 |
2020-06-09 |
Morningside Venture Investments Limited |
Craving input and support system
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
CA3049529A1
(en)
|
2017-01-06 |
2018-07-12 |
Chrono Therapeutics Inc. |
Transdermal drug delivery devices and methods
|
US11596779B2
(en)
|
2018-05-29 |
2023-03-07 |
Morningside Venture Investments Limited |
Drug delivery methods and systems
|